• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.

Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.

June 28, 2013 By Arezu Sarvestani

Stent Wars logo

A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court’s ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.

Device makers Abbott (NYSE:ABT), Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) cemented their previous win the in long-running battle over drug-eluting stent technology and a coating drug called rapamycin.

A 3-member panel of judges for the Federal Circuit ruled this week to invalidate patents held by Cordis and Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc. (NYSE:PFE).

The judges’ decision hinged on whether the patents in question described an invention that a skilled practitioner could reasonably make and use without "undue experimentation," a measure that’s intended to ensure that "the invention is communicated to the interested public in a meaningful way," according to the U.S. Patent & Trademark Office.

The Federal Circuit judges ruled, like their lower court counterparts, that the Wyeth patents, as written, did require undue experimentation due to the "need to engage in a systematic screening process for each of the many rapamycin candidate compounds," according to the filed decision.

J&J’s Cypher stent, the 1st drug-eluting stent to hit the U.S. market, is coated in sirolimus (also called rapamycin and rapamune), the patents for which are held by Wyeth.

J&J and Wyeth claimed that Abbott’s Xience V DES and Medtronic’s Endeavor stent were using related drugs without permission. The drug coatings help prevent scarring in the blood vessels that can occur after angioplasty procedures, keeping the vessels from re-narrowing.

Boston Scientific got pulled into the lawsuit because its Promus stent is a private-label version of the Xience V, licensed from Abbott. The Xience V and Promus stents are coated in everolimus.

Medtronic’s Endeavor is coated in zotarolimus. Both everolimus and zotarolimus are made by modifying the sirolimus molecule at a single location.

Filed Under: Drug-Eluting Stents, Legal News, News Well, Patent Infringement Tagged With: Abbott, Boston Scientific, Cordis Corp., Johnson and Johnson, Pfizer, Stent Wars, Wyeth

More recent news

  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Intuitive Surgical is making a CEO change

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy